These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2885493)

  • 1. LHRH analogues and bone loss.
    Devogelaer JP; Nagant de Deuxchaisnes C; Donnez J; Thomas K
    Lancet; 1987 Jun; 1(8548):1498. PubMed ID: 2885493
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between gonadotrophin-releasing hormone analogue therapy and bone loss; a review.
    Fraser IS
    Reprod Fertil Dev; 1991; 3(1):61-9. PubMed ID: 1957015
    [No Abstract]   [Full Text] [Related]  

  • 3. [LH-RH derivative].
    Miyake H; Fujisawa M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():313-6. PubMed ID: 25831774
    [No Abstract]   [Full Text] [Related]  

  • 4. [Bone loss induced by GnRHa treatment in women].
    Matsuo H
    Nihon Rinsho; 2003 Feb; 61(2):314-8. PubMed ID: 12638227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gonadorelin analogs combined with anti-androgens in the treatment of bone metastasis from prostate cancer. Can their use induce osteoporosis?].
    Simonin R; Nicolino-Peltier C; Gainlet P
    Presse Med; 1989 Dec; 18(41):2023. PubMed ID: 2532342
    [No Abstract]   [Full Text] [Related]  

  • 6. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
    Ripps BA; VanGilder K; Minhas B; Welford M; Mamish Z
    J Reprod Med; 2003 Oct; 48(10):761-6. PubMed ID: 14619641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma.
    Waibel-Treber S; Minne HW; Scharla SH; Bremen T; Ziegler R; Leyendecker G
    Hum Reprod; 1989 May; 4(4):384-8. PubMed ID: 2526152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
    Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR
    Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deslorelin. D-Trp-LHRH-PEA, LHRH agonist analogue, Somagard.
    Drugs R D; 1999 Dec; 2(6):420-2. PubMed ID: 10763456
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical study of the use of LHRH (GnRH) analogs].
    Nesović M; Popović V; Micić D; Mićić J
    Srp Arh Celok Lek; 1989; 117(1-2):59-72. PubMed ID: 2678527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
    Ságodi L; Sólyom E; Lombay B; Almási A; Vámosi I
    Orv Hetil; 2012 Mar; 153(11):418-24. PubMed ID: 22390866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of renal stone formation in patients treated with luteinising hormone-releasing hormone analogues for prostate cancer: importance of bone metabolism and urine calcium.
    Diaz-Convalia E; Arrabal-Polo MA; Cano-Garcia MDC; Dominguez-Amillo A; Canales-Casco N; Arrabal-Martin M
    Int Urol Nephrol; 2018 Mar; 50(3):419-425. PubMed ID: 29374814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease flare with gonadotrophin-releasing hormone (GnRH) analogues. How serious is it?
    Scaletscky R; Smith JA
    Drug Saf; 1993 Apr; 8(4):265-70. PubMed ID: 8481213
    [No Abstract]   [Full Text] [Related]  

  • 14. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
    Taxel P; Dowsett R; Richter L; Fall P; Klepinger A; Albertsen P
    BJU Int; 2010 Nov; 106(10):1473-6. PubMed ID: 20456336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of gonadotrophin-releasing hormone analogues in gynaecology.
    Lo KW; Lau TK
    Chin Med J (Engl); 1997 Oct; 110(10):746-9. PubMed ID: 9642302
    [No Abstract]   [Full Text] [Related]  

  • 16. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?
    Riis BJ; Christiansen C; Johansen JS; Jacobson J
    J Clin Endocrinol Metab; 1990 Apr; 70(4):920-4. PubMed ID: 2138631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dramatic aggravation of prostatic cancer at the onset of treatment with an LHRH agonist].
    Boumier P; Koeger AC; Camus JP
    Presse Med; 1985 May; 14(21):1200-1. PubMed ID: 3158996
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale for the short-term use of luteinising hormone-releasing hormone analogues in the treatment of uterine myomata.
    Stovall TG
    Horm Res; 1989; 32 Suppl 1():134-6. PubMed ID: 2693324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease flare induced by luteinising hormone releasing hormone analogues in cancer patients.
    Deghenghi R; Misset JL
    Lancet; 1984 Jun; 1(8389):1302. PubMed ID: 6145013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.